Please login to the form below
Akcea
This page shows the latest Akcea news and features for those working in and with pharma, biotech and healthcare.
NICE rejects Akcea’s rare inherited disorder drug Waylivra
Akcea’s drug was handed conditional approval by the European Medicines Agency (EMA) last May, making Europe its first market. ... Waylivra was Akcea’s second drug to reach the market last year after transthyretin-related amyloidosis (ATTR)
Latest news
-
Novartis highlights emerging assets and late-stage pipeline at R&D day
TQJ230, an antisense oligonucleotide it licensed from Akcea Therapeutics in February, which reduces Lp(a), a currently untreatable risk factor for cardiovascular disease – an outcomes trial of over 7, 500 patients
-
Pfizer pays $250m upfront to Akcea for phase 2 antisense drug
The Swiss pharma group took an option on two of Akcea’s lipoprotein-targeting drug candidates in 2017. ... Founded in 2015, Akcea spun out of Ionis two years later armed with four drug candidates for treating diseases caused by lipid disorders.
-
Alnylam gains key NICE approval for Onpattro
Marketed by Ionis subsidiary Akcea Therapeutics, Tegsedi stole a march over Onpattro when it gained NICE approval in April, but now Alnylam has a matching recommendation from England’s cost watchdog.
-
UK heart deaths rise for first time in 50 years
Novartis said it will in-license Akcea’s cardiovascular drug, which could potentially treat millions of patients with elevated Lp(a), a factor that cannot be managed by lifestyle changes.
-
Twentyeight-Seven raises another $15m for non-coding RNA drugs
the likes of Ionis/Akcea and Alnylam.
More from news
Approximately 10 fully matching, plus 11 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
Standing in its way is a similarly priced antisense rival from Ionis and Akcea – Tegsedi (inotersen) – as well as Pfizer’s fast- growing Vyndaqel/Vyndamax (tafamidis), which is approved for hATTR
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
two entering the field at the same time. So it is with Alnlyam: Ionis and Akcea secured EMA approval in July for their antisense candidate Tegsedi (inotersen), while Pfizer has just
-
Deal Watch January 2017
As you sow, so shall you reap The use of options is remaining widespread as noted in the Novartis deal with Ionis and Akcea. ... 1, 700. Ionis | Akcea. Novartis. Exclusive option to licence. AKCEA-APOCIII-LRx for heart failure.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Evoke Mind+Matter
They include: Aerogen, Akcea, Allakos, Alexion, Amylyx Pharmaceuticals, Astellas, Baxter Healthcare, Bayer, Biocryst, Biogen, Biomarin, Bio-Oil, Boehringer Ingelheim, Cryoport, Colgate Palmolive, CSL Behring, Eiger BioPharmaceuticals, EIT Health,
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- A new era for UK-Japanese scientific research relations
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- Sanofi Global Health unveils new nonprofit Impact brand
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- A creative awakening – how pharma is bringing innovation to the patient journey
- Behaviour change – a maze of decisions influenced by personal habits, experiences and intentions
- My journey advancing the science in pulmonary hypertension
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Delivering content to fuel omnichannel engagement
PMHub
KVA
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
